← All trials
NCT03343327
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 19, 2018
- Primary completion
- Apr 20, 2018
- Completion date
- Apr 20, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Diurnal LimitedLead sponsor
- Emas Pharma Ltd.Collaborator
- Medical Matters InternationalCollaborator
- Brush Clinical Research Ltd.Collaborator
- Simbec-OrionOverall official - principal investigator
- Simbec-OrionCollaborator
- Voet ConsultingCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.